Viral Kinetics During 14-day Treatment with Debio-025 Demonstrate Efficient Blocking of Viral Replication in Different HCV Genotypes without Signs of Emerging Viral Resistance | Debio 025 | /

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Viral Kinetics During 14-day Treatment with Debio-025 Demonstrate Efficient Blocking of Viral Replication in Different HCV Genotypes without Signs of Emerging Viral Resistance

E. Herrmann, R. Flisiak, A. Horban, R. Crabbe, H. Porchet, V. Nicolas, P. Scalfaro, S. Zeuzern

42nd Annual Meeting of the European Association for the Study of the Liver (EASL) - April 2007 - Barcelona/Spain

(Abstract + Presentation)